Psychedelic Medicine Market: How Are Australia and Europe Shaping Global Psychedelic Access Models?
International psychedelic medicine regulation — Australia's 2023 rescheduling of psilocybin and MDMA as controlled medicines for therapeutic use, Switzerland's 723 patient authorizations in 2024, and Germany's 2025 compassionate-use program — creates the most commercially dynamic market segment, with the Psychedelic Medicine Market reflecting international regulatory innovation as...
0 Commentaires 0 Parts 211 Vue 0 Aperçu